UCB FY Consensus Earnings Estimates (Average)
In € million 2025a 2026e 2027e 2028e 2029e 2030e 2031e
Net Sales
Number of Estimates 13 13 13 12 12 11
Highest 8,976 10,915 12,529 12,836 13,798 15,014
Consensus (Mean) 7,388 8,634 9,750 10,902 11,776 12,661 13,297
Lowest 8,159 9,061 10,110 10,815 11,483 12,017
Revenue
Number of Estimates 15 15 15 14 14 12
Highest 9,593 11,278 12,913 14,146 15,455 15,486
Consensus (Mean) 7,741 9,076 10,107 11,222 12,250 13,156 13,619
Lowest 8,477 9,333 10,426 11,131 11,800 12,335
Research and Development expenses
Number of Estimates 14 14 14 13 13 12
Highest 2,141 2,579 2,774 2,856 3,015 3,079
Consensus (Mean) 1,822 2,047 2,271 2,421 2,572 2,675 2,645
Lowest 1,846 2,030 2,195 2,230 2,210 1,200
Marketing & Selling expenses
Number of Estimates 10 10 10 10 10 9
Highest 2,773 3,026 3,263 3,466 3,702 3,737
Consensus (Mean) 2,485 2,665 2,884 3,094 3,214 3,320 3,379
Lowest 2,574 2,730 2,849 2,934 3,010 2,859
General and administrative expenses
Number of Estimates 10 10 10 10 10 9
Highest 364 380 417 459 482 497
Consensus (Mean) 264 290 309 328 343 356 369
Lowest 257 258 261 263 266 269
Other operating (income)/expenses
Number of Estimates 14 14 14 14 14 12
Highest -613 -648 -672 -686 -696 -659
Consensus (Mean) -829 -823 -948 -1,037 -1,116 -1,196 -1,188
Lowest -983 -1,131 -1,263 -1,359 -1,621 -1,828
Adjusted EBIT
Number of Estimates 15 15 15 14 14 12
Highest 3,209 3,723 4,487 5,422 6,345 6,955
Consensus (Mean) 2,009 2,768 3,192 3,781 4,403 4,989 5,433
Lowest 2,219 2,779 3,194 3,791 4,128 4,359
Adjusted EBITDA
Number of Estimates 14 14 14 13 13 11
Highest 3,858 4,414 5,319 6,351 7,380 8,081
Consensus (Mean) 2,636 3,427 3,945 4,559 5,234 5,866 6,250
Lowest 2,896 3,470 3,844 4,441 5,006 5,292
Adj. EBITDA ratio
Number of Estimates
Highest
Consensus (Mean) 34.05% 37.76% 39.04% 40.62% 42.73% 44.59% 45.89%
Lowest
Net Profit
Number of Estimates 11 11 11 11 11 9
Highest 2,645 2,933 3,589 4,254 4,808 5,170
Consensus (Mean) 1,604 2,253 2,566 3,045 3,586 4,090 4,367
Lowest 1,747 2,134 2,605 3,095 3,379 3,626
Core EPS (€)
Number of Estimates 12 12 12 12 12 10
Highest 14.93 17.54 21.99 26.79 31.68 35.28
Consensus (Mean) 9.78 13.46 15.37 18.04 20.85 23.68 26.07
Lowest 11.21 13.18 15.73 17.74 19.05 20.23
UCB FY Consensus Product Sales Estimates (Average)
In € million 2025a 2026e 2027e 2028e 2029e 2030e 2031e
Product Portfolio
Cimzia
Number of Estimates 13 13 13 12 12 11
Highest 2,105 2,101 1,934 1,815 1,722 1,642
Consensus (Mean) 1,954 1,958 1,869 1,691 1,478 1,329 1,206
Lowest 1,842 1,681 1,430 1,100 950 835
Bimzelx
Number of Estimates 13 13 13 12 12 12
Highest 3,893 5,753 7,047 7,028 7,758 8,522
Consensus (Mean) 2,227 3,518 4,645 5,707 6,511 7,226 7,732
Lowest 3,180 4,088 5,040 5,702 6,130 6,439
Evenity*
Number of Estimates 13 13 13 12 12 11
Highest 204 248 297 342 376 395
Consensus (Mean) 137 186 224 255 279 296 287
Lowest 167 201 228 240 252 208
Rystiggo
Number of Estimates 13 13 13 12 12 11
Highest 450 583 720 885 1,038 1,172
Consensus (Mean) 332 429 536 633 706 767 816
Lowest 403 495 573 629 661 684
Zilbrysq
Number of Estimates 13 13 13 12 12 11
Highest 435 588 698 797 926 1,044
Consensus (Mean) 217 323 424 515 598 652 705
Lowest 266 348 435 491 535 557
Vimpat
Number of Estimates 13 13 13 12 12 11
Highest 251 219 195 195 195 195
Consensus (Mean) 303 210 182 160 144 131 120
Lowest 188 152 124 98 78 62
Keppra
Number of Estimates 13 13 13 12 12 11
Highest 438 409 400 400 380 360
Consensus (Mean) 439 410 372 341 319 297 276
Lowest 363 309 262 224 186 159
Briviact
Number of Estimates 13 13 13 12 12 11
Highest 563 448 430 447 459 469
Consensus (Mean) 758 498 287 235 215 197 187
Lowest 448 170 107 85 77 69
Fintepla
Number of Estimates 13 13 13 12 12 11
Highest 557 687 807 934 1,078 1,079
Consensus (Mean) 427 517 626 708 763 801 795
Lowest 500 579 637 666 600 540
Nayzilam
Number of Estimates 13 13 13 12 12 11
Highest 177 203 223 210 214 218
Consensus (Mean) 128 168 179 174 149 129 122
Lowest 143 150 143 103 50 50
Kygevvi
Number of Estimates 1 9 10 10 10 10 9
Highest 0 47 95 142 190 237 291
Consensus (Mean) 0 23 45 71 99 130 144
Lowest 0 10 13 20 25 30 35
Potential New Products non-risk adjusted
Dapirolizumab pegol
Number of Estimates 1 2 2 5 7 8 8
Highest 0 0 0 290 522 783 1,018
Consensus (Mean) 0 0 0 78 176 283 429
Lowest 0 0 0 0 30 50 113
Staccato alprazolam
Number of Estimates 2 3 5 7 7 7 6
Highest 0 0 81 146 211 276 222
Consensus (Mean) 0 0 33 58 102 143 151
Lowest 0 0 0 7 10 13 17
Rezanecel
Number of Estimates 1 1 1 3 4 5
Highest 0 0 0 65 167 526
Consensus (Mean) 0 0 0 25 117 293
Lowest 0 0 0 0 0 70
Bepranemab
Number of Estimates 1 2 2 4 4 5 5
Highest 0 0 0 165 413 600 873
Consensus (Mean) 0 0 0 55 156 217 363
Lowest 0 0 0 0 9 30 180
Galvokimig (UCB9741)
Number of Estimates 1 2 2 3 5 6 7
Highest 0 0 0 0 300 650 800
Consensus (Mean) 0 0 0 0 90 341 451
Lowest 0 0 0 0 0 171 103
Cizutamig
Number of Estimates 1 1 1 1 2 3
Highest 0 0 0 0 10 210
Consensus (Mean) 0 0 0 0 5 103
Lowest 0 0 0 0 0 0

*European sales, ex-EU sales booked by Amgen/Astellas